The versatility of the Randox multiplex PCR and proprietary Biochip Array
Technology is exemplified by the broad range of array formats available. These
include:
- SNP
Genotyping: Based on an innovative primer design which can discriminate
sequences which differ only at one base.
- Gene
Expression: Harnessing gene expression, particularly in a multiplex array,
can provide a powerful insight into disease processes, such as cancer
progression.
- Pathogen
Detection: For rapid, sensitive, multiplex detection of viral, bacterial
and protozoan pathogens.
- Mutation
Detection: A rapid mutation profiling array, consisting of a highly
multiplexed PCR coupled to hybridisation of target DNA sequences to
spatially tethered probes on a biochip array.
Our Sexually Transmitted Infection (STI) Array is capable of simultaneously
detecting ten of the most common STIs from a single patient sample. STIs
represent a serious public health issue and as many are asymptomatic, the risk
of unhindered spread is increased. Simultaneous screening for multiple STIs
will identify specific viral, protozoan or bacterial pathogens therefore
permitting targeted therapy whilst also detecting secondary infections.
The Respiratory Pathogens Array simultaneously detects up to 22 viral
and bacterial infectious agents of the respiratory tract from Bronchoalveolar
lavage, Nasopharyngeal swab, Sputum or Saliva. By detecting both viral and
bacterial pathogens simultaneously, this array provides a rapid and more cost
effective diagnostic tool than existing methods, the majority of which only look
for single pathogens.
Personalised cancer medicine based on genetic
profiling of individual tumours is regarded as the treatment strategy of the
future. In respect of this, Randox Molecular Diagnostics will soon be launching
a
KRAS/BRAF/PIK3CA Array for the rapid and accurate detection of
mutations to stratify patients for anti-EGFR-targeted therapy. This is
important, as recent clinical evidence indicates that in addition to
KRAS mutational
status, other molecular alterations such as
BRAF and PIK3CA mutations
can occur in a tumour, precluding response to anti-EGFR therapy.
With such remarkable innovations, Randox Molecular
Diagnostics is truly changing this fast paced market. This is the future of
diagnostics and we are dedicated to providing the highest quality and most
reliable solutions.
About Randox
Headquartered in the United Kingdom, Randox Laboratories Ltd. is a
market leader within the
in vitro
diagnostics industry, manufacturing high quality diagnostic products for
laboratories worldwide. Our extensive product portfolio offers complete
solutions within the fields of clinical chemistry, cardiology, forensic
toxicology, veterinary, drug residues, life sciences, oncology, molecular
diagnostics and internal and external quality control. Our goal is to
‘revolutionise healthcare through continuously improving diagnostic solutions.'
We continue to achieve this year after year due to our commitment and
significant re-investment in Research and Development. Our innovative approach
to diagnostics allows us to develop revolutionary products, specifically
designed to provide more efficient, higher quality and reliable results,
ensuring patients receive the right diagnosis at the right time.
For more
information contact us at marketing@randox.com
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.